NCT04225039 - Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

September 8, 2022

Study Completion Date

April 30, 2029

Conditions

Glioblastoma

Interventions

DRUG

INCMGA00012

500mg IV neoadjuvant treatment; 500 mg adjuvant treatment

DRUG

INCAGN01876

300mg IV neoadjuvant treatment; 300 mg adjuvant treatment

DRUG

SRS

administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).

PROCEDURE

Brain surgery

maximal safe surgical resection of the tumor.

Trial Locations (1)

Hospital of the University of Pennsylvania, Philadelphia